REGENXBIO Inc. (RGNX)
Chart Events
Performance Outlook
| Previous Close | 39.98 |
| Open | 40.10 |
| Bid | 26.56 x 900 |
| Ask | 46.27 x 800 |
| Day's Range | 38.97 - 41.27 |
| 52 Week Range | 20.03 - 50.26 |
| Volume | 390,956 |
| Avg. Volume | 495,955 |
| Market Cap | 1.731B |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.47 |
| Earnings Date | Mar 01, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.89 |
Fair Value
Related Research
- PR Newswire
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following March investor conferences, which will each be held in a virtual meeting format:
- PR Newswire
REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, March 1, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2020, and recent operational highlights.
- Benzinga
Regenxbio Gene Therapy Shows Treatment Benefit In Wet AMD Study
Regenxbio Inc (NASDAQ: RGNX) has reported additional interim data from Cohorts 4 and 5 of its Phase 1/2a trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) and Cohort 3 of its Long-Term Follow-Up (LTFU) study. As of January 22, RGX-314 continued to be generally well-tolerated across all cohorts, with 20 serious adverse events (SAEs) reported in 13 patients, including one possibly drug-related SAE of a significant decrease in vision in Cohort 5. Patients in Cohorts 4 and 5 at 1.5 years after administration of RGX-314 demonstrated stable visual acuity and decreased central retinal thickness (CRT). A meaningful reduction in anti-VEGF treatment burden was observed in both Cohorts 4 and 5 compared to the mean annualized injection rate during the 12 months before RGX-314 administration. Patients in Cohort 4 and Cohort 5 received a mean of 4.4 injections and 1.7 injections over 1.5 years following administration of RGX-314, a 58.3% and 81.2% reduction in anti-VEGF treatment burden, respectively. Following the Phase 1/2a trial, patients can enroll in a long-term study to assess the safety and efficacy up to five years after RGX-314 administration. All six patients from Cohort 3 of the Phase 1/2a trial enrolled in the LTFU study and demonstrated a mean BCVA improvement of +12 letters from baseline at three years. Patients also demonstrated long-term reductions in anti-VEGF treatment burden over three years with a mean annualized rate of 2.4 anti-VEGF injections, a 66.7% reduction. Price Action: RGNX stock closed 0.8% lower at $46.96 on Friday. See more from BenzingaClick here for options trades from BenzingaExelixis' Cabozantinib Shows Overall Objective Response Rates of 38% In Genitourinary Tumor SettingsExelixis' Cabozantinib Data Shows Clinically Significant Benefit Versus Pfizer's Sutent, In A Type Of Kidney Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
